Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a postmenopausal woman with a rare instance of ovarian fibrothecoma exhibiting virilizing features, who presented with symptoms such as excess hair growth and clitoromegaly.

This study found that for postmenopausal patients with advanced breast cancer, quality of life, overall survival, and progression-free survival are the most important factors in treatment decisions, while side effects hold less importance.

This review provides a detailed analysis of frontal fibrosing alopecia, focusing on its prevalence in postmenopausal Caucasian women, associated comorbidities, and potential autoimmune, genetic, hormonal, and environmental factors; it emphasizes the need for improved understanding to enhance diagnosis and treatment.

This case report describes a post-menopausal woman with severe hirsutism whose high testosterone levels decreased after gonadotropin suppression, indicating residual hormone-producing tissue responsive to gonadotropins.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This case report details a post-menopausal woman with hirsutism and virilization due to rare Leydig cell tumors in both ovaries, underscoring the challenge of detecting such tumors with standard imaging.

This study observed that frontal fibrosing alopecia predominantly affects postmenopausal women, can be associated with lichen planus, and may lead to progressive hairline recession, though this progression is not consistent in all cases.

This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.

This review examines hair and skin disorders in post-menopausal women and notes a lack of evidence supporting specific treatments for this population.

This review discusses the impact of testosterone therapy on postmenopausal women's sexual function and well-being but notes a lack of long-term safety studies and debates on defining androgen insufficiency.

This article describes various acute and chronic vulvar disorders post-menopause and summarizes identification and treatment strategies, but reports no new clinical findings.

This case series observed that ovarian hyperthecosis can manifest with hyperandrogenism and insulin resistance in postmenopausal women, even when serum testosterone levels are below diagnostic thresholds, suggesting potential gaps in current diagnostic criteria.

This article discusses the sexual health issues faced by postmenopausal women and highlights the need for more research and tailored treatments, but it reports no new clinical results.

This case study suggests that low leptin levels in obese hyperandrogenic postmenopausal women might indicate the presence of androgen-secreting tumors.

This case study describes an 88-year-old postmenopausal woman diagnosed with Sertoli-Leydig cell tumor, a rare ovarian cancer, highlighting the importance of checking hormone levels in similar unexpected cases.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This case study highlights the challenges of diagnosing hyperandrogenism in postmenopausal women, reporting a patient with androgenic alopecia and high testosterone due to a benign Leydig cell tumor in the ovary; surgery successfully normalized testosterone levels.

This case study reported on a 62-year-old woman with ovarian hyperthecosis, which caused symptoms like hirsutism and elevated testosterone; after bilateral oophorectomy, her symptoms improved, suggesting the importance of considering this rare condition in hyperandrogenism diagnosis for postmenopausal women.

This mini-review examines ethnopharmacological approaches to manage hair loss in postmenopausal women, highlighting promising botanical remedies like saw palmetto, rosemary oil, and ginseng. The authors underscore a need for more interdisciplinary trials and focus on traditional remedies' multifaceted benefits, while noting gaps in menopausal-specific evidence.

This study reports that subcutaneous testosterone pellets in peri- and postmenopausal women provided sustained hormone release and potential benefits for sexual function, but raised concerns about safety, variability, and dosing inconsistencies.

This case study reported that sudden hyperandrogenism in postmenopausal women may indicate hormonally active ovarian tumors such as Leydig cell tumors, which can be effectively treated with surgery.

Frontal fibrosing alopecia is a scarring hair loss condition mainly affecting postmenopausal women, with unclear causes.

This case report describes a 52-year-old postmenopausal woman diagnosed with a rare Steroid Tumor Without Other Specification, highlighting the diagnostic challenges and treatment approach involving bilateral salpingo-oophorectomy.

This paper presents two cases of frontal fibrosing alopecia in postmenopausal women, noting challenges in monitoring due to the invasive nature of the diagnostic process.

This case report describes a 65-year-old postmenopausal woman with hyperandrogenism caused by a non-malignant ovarian Leydig cell tumor, which is a rare cause of virilization.

This report presents a rare case where a bilateral ovarian thecoma in a postmenopausal woman led to an unusual pattern of female androgenetic alopecia mimicking male pattern hair loss.

In this study, among postmenopausal women with female androgenetic alopecia, the combination of Pygeum africanum and Serenoa repens extracts at higher doses plus MSM significantly increased total hair growth and hair resistance compared to a lower dose formulation after 16 weeks.

This study found that breast cancer treatment with chemotherapy, radiotherapy, and/or hormonal therapy led to a significant increase in blood urea and creatinine levels, indicating nephrotoxicity among non-diabetic, non-cardiac post-menopausal patients with infiltrating ductal carcinoma.

This report describes an exceptionally rare adrenal neoplasm in a post-menopausal woman that exclusively secreted DHEA-S, with significant serum level reduction following adrenalectomy.

This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.